The DOI matches its Crossref record; 111 of the 113 references it cites were found in a registry or an index.
Microfluidic Liver-on-a-Chip for Preclinical Drug Discovery
Open accessAbstract
Drug discovery is an expensive, long, and complex process, usually with a high degree of uncertainty. In order to improve the efficiency of drug development, effective methods are demanded to screen lead molecules and eliminate toxic compounds in the preclinical pipeline. Drug metabolism is crucial in determining the efficacy and potential side effects, mainly in the liver. Recently, the liver-on-a-chip (LoC) platform based on microfluidic technology has attracted widespread attention. LoC systems can be applied to predict drug metabolism and hepatotoxicity or to investigate PK/PD (pharmacokinetics/pharmacodynamics) performance when combined with other artificial organ-on-chips. This review discusses the liver physiological microenvironment simulated by LoC, especially the cell compositions and roles. We summarize the current methods of constructing LoC and the pharmacological and toxicological application of LoC in preclinical research. In conclusion, we also discussed the limitations of LoC in drug discovery and proposed a direction for improvement, which may provide an agenda for further research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 (A) Cell distribution structure in a liver lobule. Double blood supply of hepatic arteriole and portal vein enters the liver’s portal triad region and the central vein. (B) Three-dimensional liver tissue diagram in LoC. The fluid flows through the pores on the scaffold, providing the biochemical environment and mechanical stimulation. (C) Microstructure of liver. The liver lobule is hexagonal, with a 1 mm diameter and a 2 mm thickness, functionally divided into three regions. (D) Example of zonal heterogeneity of hepatotoxicity. The yellow arrow shows the flow direction. (A,B) reproduced with permission of [34], Copyright © 2017. Published by Elsevier. (C,D) reproduced with permission of [29], Copyright © 2019. Published by MDPI.](https://figures.cochat.ai/paper-figures/8eeeeaa0612e4f01b3c2ef7d6ea2cc89/microfluidic-liver-on-a-chip-for-preclinical-drug-discovery-figure-1.jpg)
![Figure 2 Different microfluidic models are used to construct liver-on-a-chip. (A) A 24-well PDMS mold with through holes at the bottom. Hepatocytes (labeled green) selectively adhered to the collagen structure, clustered together, and then surrounded by mouse 3T3-J2 fibroblasts (labeled orange). (B) Microfluidic endothelial-like barrier. The barrier consists of parallel channels connecting the cell culture zone with the external flow channel. (C) Simulation of liver lobules in Christmas tree structure, with gradient generator. (D) Spheroid culture. Cultured spheroids in an ultra-low-attachment plate, transferred them to a 96-well plate or liver chip and compared their performance. (A) reproduced with permission of [11], Copyright © 2008. Published by Nature Publishing Group. (B) reproduced with permission of [78], Copyright © 2007. Published by Wiley Periodicals, Inc. (C) reproduced with permission of [79], Copyright © 2018. Published by Nature Publishing Group. (D) reproduced with permission of [80], Copyright © 2022 Published by Elsevier.](https://figures.cochat.ai/paper-figures/1de44d36495d453cb996e1c2989e0ebf/microfluidic-liver-on-a-chip-for-preclinical-drug-discovery-figure-2.jpg)
![Figure 3 Example of 3D perfusion platforms. (A) Twelve fluid-isolated bioreactors with connected cell culture plate (yellow) and pneumatic plate (gray). (B) Cross section diagram of the bioreactor, the membrane separates the upper cell culture plate from the lower pneumatic plate, and the micropump provides power for medium circulation in the channel. (C) OrganoPlate LiverTox model. The iHeps differentiated in 2D culture are harvested and seeded in OrganoPlate 2-lane through a liquid processor. Perfusion and organ channels were separated by phase guidance (PhG). (A,B) reproduced with permission of [16], Copyright © 2016. Published by The American Society for Pharmacology and Experimental Therapeutics. (C) reproduced with permission of [20], Copyright © 2021. Published by Elsevier.](https://figures.cochat.ai/paper-figures/f107793bd46a470f93f5a9f2f9afd983/microfluidic-liver-on-a-chip-for-preclinical-drug-discovery-figure-3.jpg)
![Figure 4 Example of multi-organ chips platforms. (A) Multi-organ chips based on liver, intestinal, vascular, and kidney chips. Caco-2, HUVEC, HepG2, and HK-2 occupy one floor from top to bottom (B) Taking a two-layer chip assembly as an example, the system was built in the order of inoculating cells to a porous membrane, providing a cell culture medium and assembling chips. The peristaltic pump provides power for fluid. (C) The liver and lung cancer parts on chips are connected through a microchannel. Channel is also equipped with a stirrer-based micropump to provide power. The value in the arrow is the flow ratio. (D) Concept diagram of PK model based on the multi-organ chip. (A,B), reproduced with permission of [23], Copyright © 2020. Published by Elsevier. (C,D) reproduced with permission of [91], Copyright © 2020. Published by AIP Publishing.](https://figures.cochat.ai/paper-figures/52e904e88dce4befabedea31a2ed646a/microfluidic-liver-on-a-chip-for-preclinical-drug-discovery-figure-4.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Real-time monitoring of metabolic processes; transparent and flexible adjustment of physiological conditions.”
From Constructing biomimetic microenvironments for liver regeneration (2025) · doi:10.1186/s12951-025-03729-9 · cites this paper as [138]
In the citing paper
“Difficult manufacturing; challenging cell implantation; high costs; requires precise equipment; limited testing and analysis.”
From Constructing biomimetic microenvironments for liver regeneration (2025) · doi:10.1186/s12951-025-03729-9 · cites this paper as [138]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stem cells, cancer, and cancer stem cells
Reya, T., Morrison, S. J., Clarke, M. F., & Weissman, I. L. (2001) · Nature · doi:10.1038/35102167 · Cited by 9,738 · cited 1×
“They are the most primitive cells in the cell line, which can differentiate into cells of a particular tissue type in vivo [65].”
BackgroundBhatia, S. N., & Ingber, D. E. (2014) · Nature Biotechnology · doi:10.1038/nbt.2989 · Cited by 3,305 · cited 1×
“Researchers used microfluidic devices to provide oxygen, shear stress, and other conditions for cell culture in vitro, pursuing better simulation of the physiological functions of tissue and organs [73].”
MethodConcordance of the toxicity of pharmaceuticals in humans and in animals
Olson, H., Betton, G., Robinson, D., Thomas, K., Monro, A., Kolaja, G., Lilly, P., Sanders, J., Sipes, G., Bracken, W., et al. (2000) · Regulatory Toxicology and Pharmacology · doi:10.1006/rtph.2000.1399 · Cited by 2,050
From 3D cell culture to organs-on-chips
Huh, D., Hamilton, G. A., & Ingber, D. E. (2011) · Trends in Cell Biology · doi:10.1016/j.tcb.2011.09.005 · Cited by 1,834
Why 90% of clinical drug development fails and how to improve it?
Sun, D., Gao, W., Hu, H., & Zhou, S. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.02.002 · Cited by 1,763 · cited 1×
“Statistics show that the average development cost of a new drug is around two billion dollars [4].”
BackgroundHuman primary liver cancer–derived organoid cultures for disease modeling and drug screening
Broutier, L., Mastrogiovanni, G., Verstegen, M. M., Francies, H. E., Gavarró, L. M., Bradshaw, C. R., Allen, G. E., Arnes-Benito, R., Sidorova, O., Gaspersz, M. P., et al. (2017) · Nature Medicine · doi:10.1038/nm.4438 · Cited by 1,471 · cited 2×
“Typical odels include 2D planar pri ary hepatocytes [36,37], 3 ri ted liver tissue [38–41], hepatocyte organoids [42], and liver-on-ac i [43–46].”
BackgroundControlled synthesis of HBsAg in a differentiated human liver carcinoma-derived cell line
Aden, D. P., Fogel, A., Plotkin, S., Damjanov, I., & Knowles, B. B. (1979) · Nature · doi:10.1038/282615a0 · Cited by 1,317 · cited 1×
“Immortalized liver cell lines, which can be manipulated with unlimited proliferation by inhibiting cellular senescence [58,59], are widely used in drug toxicology research in vitro.”
MethodGodoy, P., Hewitt, N. J., Albrecht, U., Andersen, M. E., Ansari, N., Bhattacharya, S., Bode, J. G., Bolleyn, J., Borner, C., Böttger, J., et al. (2013) · Archives of Toxicology · doi:10.1007/s00204-013-1078-5 · Cited by 1,280 · cited 1×
“Hepatocytes, known as parenchymal cells, account for about 60% of liver cells [31].”
BackgroundMicroscale culture of human liver cells for drug development
Khetani, S. R., & Bhatia, S. N. (2008) · Nature Biotechnology · doi:10.1038/nbt1361 · Cited by 1,219 · cited 2×
“(A) reproduced with permission of [11], Copyright © 2008.”
BackgroundMethodOrgans-on-chips at the frontiers of drug discovery
Esch, E. W., Bahinski, A., & Huh, D. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4539 · Cited by 1,185 · cited 1×
“Most drug failures in clinical trials because the existing models in preclinical development are not appropriate for predicting new compound toxicity or metabolism [5].”
Background
Cited by
Microfluidic Devices: A Tool for Nanoparticle Synthesis and Performance Evaluation
Gimondi, S., Ferreira, H., Reis, R. L., & Neves, N. M. (2023) · ACS Nano · doi:10.1021/acsnano.3c01117 · Cited by 376
Application of new approach methodologies for nonclinical safety assessment of drug candidates
Beilmann, M., Adkins, K., Boonen, H. C. M., Hewitt, P. G., Hu, W., Mader, R., Moore, S., Rana, P., Steger‐Hartmann, T., Villenave, R., et al. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01182-9 · Cited by 85
Alexandre-Franco, M. F., Kouider, R., Alkarany, R. A.-K., Correa, E. M. C., & Abdulla, A. A.-K. (2024) · Micromachines · doi:10.3390/mi15091137 · Cited by 52
Brain organoids-on-chip for neural diseases modeling: History, challenges and trends
Zhang, H., Huang, N., Bian, S., & Sawan, M. (2025) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2025.101323 · Cited by 36
“This enables deeper insights into human responses to drugs and external stimuli, thereby pushing the boundaries of biomimicry in biological systems [26].”
Fayazbakhsh, F., Hataminia, F., Eslam, H. M., Ajoudanian, M., Kharrazi, S., Sharifi, K., & Ghanbari, H. (2023) · Scientific Reports · doi:10.1038/s41598-023-47291-6 · Cited by 27
Metadata
- Authors
- Fu, J., Qiu, H., & Tan, C. S.
- Affiliations
- Tianjin University (CN)
- Tianjin University of Technology (CN)
- Corresponding author
- Qiu, Hailong
- Tan, Cherie S.
- Venue
- Pharmaceutics
- Publisher
- MDPI AG
- Published
- 2023-04-21
- Volume
- 15
- Issue
- 4
- Pages
- 1300
- ISSN
- 1999-4923 (ISSN-L)
- PMC
- PMC10141038
- OpenAlex
- W4366773405
- Cited by
- 42
- References
- 113
- Citations by year
- 2026: 18 · 2025: 20 · 2024: 2 · 2023: 2
- FWCI
- 0.94
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Pharmaceutics (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Natural Science Foundation of China (22274110, 22250610197, 51872198, 21904094, 2021-JCJQ-JJ-0639, GG20210301)
- National Defense Science and Technology 173 Program (22274110, 22250610197, 51872198, 21904094, 2021-JCJQ-JJ-0639, GG20210301)
- National Key Research and Development Program of China (22274110, 22250610197, 51872198, 21904094, 2021-JCJQ-JJ-0639, GG20210301)
- Topics
- Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
- Physical Sciences › Engineering › Biomedical Engineering › Microfluidic and Capillary Electrophoresis Applications
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Keywords
- liver-on-a-chip, organ-on-a-chip, preclinical drug discovery, drug metabolism, hepatotoxicity prediction, pharmacokinetics/pharmacodynamics, liver microenvironment, drug screening
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Microfluidic Liver-on-a-Chip for Preclinical Drug Discovery. https://app.cochat.ai/papers/10.3390/pharmaceutics15041300
- The paper
- Fu, J., Qiu, H., & Tan, C. S. (2023). Microfluidic Liver-on-a-Chip for Preclinical Drug Discovery. Pharmaceutics. https://doi.org/10.3390/pharmaceutics15041300
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.